Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.54 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.54 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30786693 | 1.00 | CES2 (0.61) | CES2ALDH1A1POLBNPSR1LMNA | |
| SCHEMBL27425778 | 0.93 | MAPT (0.55) | CES2ALDH1A1POLBNPSR1LMNA | |
| SCHEMBL7471216 | 0.91 | MAPT (0.54) | CES2ALDH1A1POLBNPSR1LMNA | |
| SCHEMBL2694877 | 0.90 | TAS1R3 (0.53) | CES2ALDH1A1POLBNPSR1LMNA | |
| SCHEMBL28017646 | 0.89 | CYP4F2 (0.50) | CES2ALDH1A1POLBLMNAMAPT | |
| SCHEMBL23817363 | 0.88 | CES2 (0.54) | CES2ALDH1A1POLBNPSR1LMNA | |
| SCHEMBL31575815 | 0.87 | LMNA (0.60) | CES2ALDH1A1POLBNPSR1LMNA | |
| SCHEMBL20267329 | 0.87 | LMNA (0.60) | CES2ALDH1A1POLBNPSR1LMNA | |
| SCHEMBL9937464 | 0.87 | RAB9A (0.61) | ALDH1A1POLBMAPTMEN1KMT2A | |
| SCHEMBL1787779 | 0.87 | ACHE (0.57) | ALDH1A1POLBKMT2ACYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | BASF SE (DE) | 2019-03-05 | — | — | US | claimed |
| US-20170012208-A1 | ORGANIC SEMICONDUCTOR FORMULATIONS | USINVEST LLC | 2017-01-12 | — | — | US | claimed |
| US-8952083-B2 | Fluorocopolymer composition and its production process | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | claimed |
| EP-3183250-B1 | PROCESS FOR PREPARING CRYSTALLINE ORGANIC SEMICONDUCTOR MATERIAL | CLAP CO LTD (KR) | 2023-10-04 | — | — | EP | disclosed |
| EP-3183757-B1 | ORGANIC SEMICONDUCTOR COMPOSITION COMPRISING LIQUID MEDIUM | CLAP CO LTD (KR) | 2022-05-04 | — | — | EP | disclosed |
| CN-110272344-B | Camphorylimidazole type ionic liquid and preparation method and application thereof | 南京林业大学 | 2021-08-10 | — | — | CN | disclosed |
| CN-107004768-B | Organic semiconductor composition containing a liquid medium | 巴斯夫欧洲公司 | 2020-08-21 | — | — | CN | disclosed |
| US-10454037-B2 | Organic semiconductor composition comprising a liquid medium | BASF SE (DE) | 2019-10-22 | — | — | US | disclosed |
| CN-110272344-A | A kind of camphoryl imidazole type ion liquid and its preparation method and application | 南京林业大学 | 2019-09-24 | — | — | CN | disclosed |
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | BASF SE (DE) | 2019-03-05 | — | — | US | disclosed |
| US-10043978-B2 | Organic semiconductor formulations | FLEXTERRA, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-6610697-B1 | Treating rheumatoid arthritis | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-08-26 | — | — | US | disclosed |
| CN-1342162-A | Substituted 2-acyl-3-(heteroaryl)-imidazo [1,2-a] pyrimidines, and related pharmaceutical compoistions and methods | ORTHO MCNEIL PHARM INC (US) | 2002-03-27 | — | — | CN | disclosed |
| EP-1140939-A1 | SUBSTITUTED 2-ARYL-3-(HETEROARYL)-IMIDAZO[1,2-ALPHA]PYRIMIDINES, AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001034605-A1 | SUBSTITUTED 2-ARYL-3-(HETEROARYL)-IMIDAZO[1,2-a]PYRIMIDINES, AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-05-17 | — | — | WO | disclosed |
| US-4910206-A | Endotoxin induced lung injury | SANDOZ PHARMACEUTICALS CORP. (US) | 1990-03-20 | — | — | US | disclosed |
| US-4322429-A | Isoxazolylbenzamides as insecticides | ELI LILLY AND COMPANY (US) | 1982-03-30 | — | — | US | disclosed |
| EP-0048162-A1 | Isoxazolylbenzamides | ELI LILLY AND COMPANY (US) | 1982-03-24 | — | — | EP | disclosed |
| US-4140859-A | Dilithiated 2-(o-tolyl)-2-imidazolines | SANDOZ, INC. (US) | 1979-02-20 | — | — | US | disclosed |
| US-4101553-A | Imidazo[2,1-a]isoquinolines | SANDOZ, INC. (US) | 1978-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10454037-B2 | Organic semiconductor composition comprising a liquid medium | CRY1, NEFM, OR10J3 | CES2 4077/4885ALDH1A1 4298/4885POLB 1747/4885 |
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | STOM, SPOP, TTR | CES2 3220/4885ALDH1A1 4757/4885POLB 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.